Classifications: thrombolytic enzyme, tissue plasminogen activator; Therapeutic: thrombolytic enzyme
Pregnancy Category: C
50 mg vial
Tenecteplase is a third generation thrombolytic agent with advantages over alteplase, including longer half-life, more rapid
thrombolysis, and greater fibrin specificity. Additionally, rate of noncerebral bleeding is less than in alteplase. Activates
plasminogen, a substance created by endothelial cells in response to arterial wall injury that contributes to clot formation.
Plasminogen is converted to plasmin which breaks down the fibrin mesh that binds the clot together, thus dissolving the
Effective in producing thrombolysis of a clot involved in a myocardial infarction.
Reduction of mortality associated with acute myocardial infarction (AMI).
Active internal bleeding; history of CVA; intracranial or intraspinal surgery with 2 mo; intracranial neoplasm; arteriovenous
malformation, or aneurysm; known bleeding diathesis; brain tumor; increased intracranial pressure; coagulopathy; head trauma;
stroke; surgery; severe uncontrolled hypertension; pregnancy (category C), lactation.
Recent major surgery, previous puncture of compressible vessels, CVA, recent GI or GU bleeding, recent trauma; hypertension,
mitral valve stenosis, acute pericarditis, bacterial endocarditis; severe liver or kidney disease; hemorrhagic ophthalmic
conditions; septic thrombophlebitis or occluded, infected AV cannula; advanced age; concurrent administration of oral anticoagulants,
recent administration of GP IIb/IIIa inhibitors, condition involving bleeding. Safety and efficacy in children are not established.
Route & Dosage
|Acute Myocardial Infarction
Adult: IV Infuse dose over 5 sec, <60 kg, 30 mg; 6070 kg, 35 mg; 7080 kg, 40 mg; 8090 kg, 45 mg; >90 kg, 50 mg
PREPARE: Direct: Read and follow instructions supplied with TwinPakTM Dual Cannula Device. Withdraw 10 mL of sterile
water for injection from the supplied vial; inject entire contents into the TNKase vial directing the diluent stream into
the powder. Gently swirl until dissolved but do not shake. The resulting solution contains 5 mg/mL. Withdraw the appropriate
dose and discard any unused solution. Follow directions supplied with TwinPakTM for proper handling
ADMINISTER: Direct: Dextrose-containing IV line must be flushed before and after bolus with NS. Give as a single bolus dose over 5 sec. The
total dose given should not exceed 50 mg.
INCOMPATIBILITIES Solution/additive: Dextrose solutions.
- Store unopened TwinPakTM at ≤30° C (86°
F) or under refrigeration at 2°8° C (36°46° F).
Adverse Effects (≥1%)Hematologic: Major bleeding, hematoma,
GI bleed, bleeding at puncture site, hematuria, pharyngeal, epistaxis.
Diagnostic Test Interference
Unreliable results for coagulation test I and measures of fibrinolytic activity.
In liver. Half-Life:
Assessment & Drug Effects
- Avoid IM injections and unnecessary handling or invasive procedures for the first few hours after treatment.
- Monitor for S&S of bleeding. Should bleeding occur, discontinue concomitant heparin and antiplatelet therapy; notify physician.
- Monitor cardiovascular and neurologic status closely. Persons at increased risk for life-threatening cardiac events include
those with: A high potential for bleeding, recent surgery, severe hypertension, mitral stenosis and atrial fibrillation,
anticoagulant therapy, and advanced age.
- Lab tests: Baseline and 1 h after administration of drug determine cardiac enzymes, circulating myoglobin, cardiac troponin-1,
creatine kinase-MB; Hgb & Hct post-infusion.
- Coagulation parameters may not predict bleeding episodes.
Patient & Family Education
- Notify physician of the following immediately: A sudden, severe headache; any sign of bleeding; signs or symptoms of hypersensitivity
(see Appendix F).
- Stay as still as possible and do not attempt to get out of bed until directed to do so.